Figure 6.

Senolytic tool agent Navitoclax and AD80 attenuate senescent AEC CM-mediated collagen secretion. Conditioned medium with 2.5 μM Navitoclax and 200 nM Nintedanib, ABT-317, ruxolitinib, or AD80 AEC treatment conditions from Figure 5 were diluted 1:3 in fibroblast starve medium and transferred to NHLFs for 5 days. Supernatants were assayed for collagen 1 with MSD kits. Data are presented as a percentage of the DMSO control in the matched treatment condition. Statistical analysis was performed using a two-way ANOVA and a Dunnett’s multiple comparisons test in GraphPad Prism versus each group’s DMSO control: ^*p < 0.05 and ^****p < 0.0001. Data is representative of three independent experiments accounting for 3 biological donors of AECs and 2 donors of NHLFs. Error bars represent SEM of n = 5 (DMSO controls) or n = 2 (treatments) technical replicates.